Main
/Trials
Found:
10 trials shown from 1172 total

Biomarkers in Samples From Patients With Endometrial Cancer

Estimated study start date: 31 January 2100

This research study is studying biomarkers in samples from patients with endometrial cancer. Studying samples from patients with cancer in the laboratory may help doctors learn mor

Study number:
NCT01199250
Cohorts:
1
Study phase:
N/A
Overall status:
Not yet recruiting
Study type:
Observational, Biomarker

Adjuvant Treatment for Incomplete Resection Thymoma or Thymic Carcinoma

Estimated study start date: 1 December 2023

This study is designed to investigate whether adjuvant radiochemotherapy after incomplete resection has a better survival than adjuvant radiotherapy for thymoma or thymic carcinoma.

Study number:
NCT02633514
Cohorts:
1
Study phase:
3
Overall status:
Recruiting
Study type:
Local/Regional therapies, Chemotherapy

Astrazeneca

Key trial

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer

Estimated study start date: 23 November 2023

This is a Phase III, randomised, open-label, 3-arm, multicentre, international study assessing the efficacy and safety of Dato-DXd with or without durvalumab compared with investig

Study number:
NCT06103864
Cohorts:
1
Study phase:
3
Overall status:
Recruiting
Study type:
Immunotherapy, Targeted therapy

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

Estimated study start date: 16 November 2023

The primary objective of this study is to compare progression-free survival (PFS) in participants who receive sotorasib with platinum doublet chemotherapy versus participants who r

Study number:
NCT05920356
Cohorts:
1
Study phase:
3
Overall status:
Not yet recruiting
Study type:
Chemotherapy, Targeted therapy

Astrazeneca

Key trial

An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)

Estimated study start date: 5 October 2023

This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard adjuvant endocrine therapy for patients with ER+/HER2- early breast cancer wit

Study number:
NCT05952557
Cohorts:
1
Study phase:
3
Overall status:
Recruiting
Study type:
Hormonal therapy

Metronomic Capecitabine, Oxaliplatin and UGT1A1 Genotype-directed Irinotecan in Metastatic Pancreatic Cancer Patients

Estimated study start date: 30 August 2023

This is a single-centre, non-randomized, open label phase II trial to be conducted at the National Cancer Centre, Singapore (NCCS). Patients diagnosed with metastatic PDAC will be

Study number:
NCT05929885
Cohorts:
1
Study phase:
2
Overall status:
Not yet recruiting
Study type:
Any

A Phase 2 Study of Osimertinib and S-1 in Treatment Resistant EGFR Mutant NSCLC

Estimated study start date: 1 August 2023

The objective of this study is to determine overall response rate to combination of S-1 and Osimertinib in treatment-resistant EGFR mutant lung cancer.

Study number:
NCT05773092
Cohorts:
1
Study phase:
2
Overall status:
Not yet recruiting
Study type:
Targeted therapy

A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer

Estimated study start date: 28 July 2023

This study will evaluate the efficacy and safety of inavolisib in combination with Phesgo (pertuzumab, trastuzumab, and rHuPH20 injection for subcutaneous use) compared with placeb

Study number:
NCT05894239
Cohorts:
1
Study phase:
3
Overall status:
Recruiting
Study type:
Any

A Study to Investigate Safety and Efficacy of Osimertinib and Amivantamab in Participants With Non-small Cell Lung Cancer With Common Epidermal Growth Factor Receptor Mutations

Estimated study start date: 18 July 2023

This study will assess the safety and efficacy of Osimertinib with Amivantamab as First-line Treatment in Participants with Epidermal Growth Factor Receptor Mutation-Positive, Loca

Study number:
NCT05801029
Cohorts:
1
Study phase:
2
Overall status:
Not yet recruiting
Study type:
Targeted therapy

Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC)

Estimated study start date: 27 June 2023

This study will assess the safety and efficacy of Single Tremelimumab Regular Interval Durvalumab (STRIDE) as first-line therapy in participants with advanced unresectable HCC.

Study number:
NCT05883644
Cohorts:
1
Study phase:
3
Overall status:
Not yet recruiting
Study type:
Immunotherapy